A rescue inhaler, also known as a reliever inhaler, is a medication device commonly used by individuals with respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD). It contains a fast-acting bronchodilator medication that helps open up airways during an asthma attack or breathing difficulties. This medication quickly eases symptoms like wheezing, shortness of breath, and chest tightness. Rescue inhalers offer rapid relief, but they do not treat the underlying cause of the condition. They are an essential tool for managing acute respiratory symptoms and improving the patient’s quality of life.

 Market Dynamics:

Rising prevalence of respiratory diseases, increasing geriatric population, and rising healthcare expenditure are anticipated to drive growth of the global rescue inhaler market over the forecast period. Moreover, technological advancements is also expected to boost the growth of the global rescue inhaler market over the forecast period. High growth potential in emerging markets, growing demand for home care settings, development of biologics for asthma, rising focus on telehealth for respiratory care are expected to create growth opportunities for the global rescue inhaler market during the forecast period.

However, stringent regulatory requirements, side effects of inhalers, and high cost of inhalers are expected to hamper growth of the rescue inhaler market over the forecast period.

Key features of the study:

• This report provides an in-depth analysis of the rescue inhaler market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the rescue inhaler market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

• Key companies covered as a part of this study include GSK plc., Teva Pharmaceutical Industries Ltd., Cipla Inc., PARI Pharma GmbH, Lupin, AstraZeneca, Boehringer Ingelheim International GmbH., Novartis, Pfizer, Sunovion Pharmaceuticals, 3M, OMRON Healthcare Co., Ltd., Koninklijke Philips N.V., Schiller, and Teleflex Incorporated

• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The rescue inhaler market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the rescue inhaler market

Rescue Inhaler Market Detailed Segmentation:

• By Product Type:
  • Metered Dose Inhalers
  • Dry Powder Inhalers
  • Nebulizers
  • Soft Mist Inhalers
  • Others
• By Indication:
  • Asthma
  • COPD
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Others
• By Patient Type:
  • Adult
  • Pediatric
• By Dosage Form:
  • Capsules
  • Solution
  • Suspension
  • Others
• By End User:
  • Home Care Settings
  • Hospitals & Clinics
• By Region:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East
  • Africa

Company Profile:

• GSK plc.
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• PARI Pharma GmbH
• Lupin
• AstraZeneca
• Boehringer Ingelheim International GmbH.
• Novartis
• Pfizer
• Sunovion Pharmaceuticals
• 3M
• Omron Healthcare
• Koninklijke Philips N.V.
• Invacare
• Schiller
• Teleflex Incorporated